Castle Biosciences Inc (CSTL)vsDanaher Corporation (DHR)
CSTL
Castle Biosciences Inc
$25.27
-0.32%
HEALTHCARE · Cap: $743.28M
DHR
Danaher Corporation
$187.15
-1.55%
HEALTHCARE · Cap: $134.43B
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 7037% more annual revenue ($24.57B vs $344.23M). DHR leads profitability with a 14.7% profit margin vs -7.0%. DHR earns a higher WallStSmart Score of 60/100 (C).
CSTL
Avoid31
out of 100
Grade: F
DHR
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CSTL.
Margin of Safety
-38.6%
Fair Value
$135.07
Current Price
$187.15
$52.08 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 22.2%
Generating 1.7B in free cash flow
Areas to Watch
0.8% revenue growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -5.2% — below average capital efficiency
Premium valuation, high expectations priced in
4.6% revenue growth
ROE of 7.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CSTL
The strongest argument for CSTL centers on Debt/Equity, Altman Z-Score, Price/Book.
Bull Case : DHR
The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. PEG of 1.23 suggests the stock is reasonably priced for its growth.
Bear Case : CSTL
The primary concerns for CSTL are Revenue Growth, Market Cap, Piotroski F-Score.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Revenue Growth, Return on Equity.
Key Dynamics to Monitor
CSTL profiles as a turnaround stock while DHR is a value play — different risk/reward profiles.
CSTL carries more volatility with a beta of 1.13 — expect wider price swings.
DHR is growing revenue faster at 4.6% — sustainability is the question.
DHR generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
DHR scores higher overall (60/100 vs 31/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Castle Biosciences Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Castle Biosciences Inc. is a pioneering company in the diagnostics sector, focused on transforming patient care through its innovative gene-expression profiling tests, particularly in skin cancer. Its leading product, DecisionDx®-Melanoma, plays a crucial role in the management of melanoma by providing vital insights into risk stratification and guiding treatment decisions based on gene expression analysis. Committed to advancing precision medicine, the company leverages its proprietary technology to develop additional assays that address significant clinical needs. With a strong emphasis on research and development and a promising pipeline, Castle Biosciences is well-positioned for sustainable growth while enhancing clinical outcomes and delivering value to shareholders in the dynamic oncology market.
Visit Website →Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?